2026-03-18 20:08:39
Sera Prognostics Reports Q4 2025 Results with Revenue of $10,000 and Net Loss of $7.9 Million
Expected Stock impact: Slightly Negative
Sera Prognostics, Inc. (Nasdaq: SERA), a company focused on improving maternal and neonatal health, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a revenue of $10,000 for Q4 2025, a decrease from $24,000 in the same quarter of the previous year. Total operating expenses for the quarter were $9.0 million, slightly down from $9.4 million in Q4 2024. Research and development expenses increased to $3.2 million from $3.1 million year-over-year, while selling, general, and administrative expenses decreased to $5.7 million from $6.3 million. The net loss for the quarter was $7.9 million, compared to a net loss of $8.6 million in Q4 2024. For the full year 2025, Sera reported total revenue of $81,000, up from $77,000 in 2024, with total operating expenses of $36.6 million, slightly down from $36.7 million in the previous year. The company’s net loss for the year was $31.9 million, an improvement from $32.9 million in 2024. As of December 31, 2025, Sera had cash and cash equivalents of approximately $95.8 million, which is expected to fund the company through significant adoption and commercial milestones until 2028. The company also highlighted key achievements, including the publication of the PRIME Study, which demonstrated the effectiveness of its PreTRM blood test in reducing preterm births and complications. Despite the challenges reflected in the financial results, Sera's ongoing efforts to expand its commercial engagement and strengthen its leadership team position it for future growth.
